Biosimilar Retacrit® in the Treatment of Chemotherapy-induced Anaemia in Oncology and Haematology

Inclusion Criteria: * Adult patients, aged 18 years and older, seen by the oncologist or hematologist for chemotherapy. * Patients for whom the oncologist or hematologist has decided the initiation of an epoetin alpha biosimilar treatment (Retacrit®) for anemia. * Patients informed about the computer processing of their medical data and their right of access and correction. Exclusion Criteria: * Patients with hemoglobin concentrations \>11 g/dL. * Patients who have been transfused within the previous month. * Patients who are hypersensitive to erythropoietin or one of its excipients. * Patients participating or having participated in the previous month in a clinical trial in the field of anaemia in oncology. * Patients refusing to participate in the observational study.